Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 13,084 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

Zenith® p-Branch® Endovascular Graft Pivotal Study

NCT02396199
Conditions
Aortic Aneurysm Abdominal
Interventions
Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
Conditions
Heart Failure
Interventions
Cardiac resynchronization therapy
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
34
States / cities
Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 31 more
Conditions
Solid Malignancies, Hematologic Malignancies
Interventions
IM-1021
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 16 more
Completed Phase 2 Interventional Results available

A New Oral Treatment For Type II Diabetes Mellitus

NCT00111800
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
36
States / cities
Long Beach, California • Pasadena, California • Denver, Colorado + 32 more
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more
Conditions
Neoplasms, Head and Neck
Interventions
GSK1363089 (foretinib)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 8 more
Conditions
Carcinoma, Squamous Cell, Skin Neoplasms
Interventions
Pembrolizumab, Intismeran autogene, Surgery
Biological · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 17 more
Conditions
Atrial Fibrillation, Inflammation
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Ventilator Associated Pneumonia, Nosocomial Infections in Children, Microbial Colonization
Interventions
Development and implementation of an antibiotic guideline
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 3 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Conditions
Acute Myeloid Leukemia
Interventions
Tamibarotene, Venetoclax, Azacitidine
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 10 more
Conditions
Hyperglycemia Stress
Interventions
Dulaglutide, Placebo, Continuous glucose monitor (CGM), blinded
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
34
States / cities
Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more
Conditions
Submassive Pulmonary Embolism
Interventions
catheter-directed thrombolysis
Procedure
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Candidiasis, Candidemia
Interventions
Micafungin, Caspofungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
62
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Montgomery, Alabama • Bullhead City, Arizona • Phoenix, Arizona + 56 more
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Conditions
Driveline Heart-assisted Device Related Infection
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
15
States / cities
New Haven, Connecticut • Tampa, Florida • Atlanta, Georgia + 12 more
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 9 more
Conditions
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
Interventions
Docetaxel, Combination of ganetespib and docetaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Tucson, Arizona • Santa Monica, California • Atlanta, Georgia + 5 more
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Conditions
Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)
Interventions
Blood Draw
Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 20 more
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
West Hollywood, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
5 Days to 16 Years
Enrollment
1,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
25
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 20 more
Conditions
Cerebral Palsy
Interventions
Virtual Reality, Functional Strength Training
Other
Lead sponsor
Georgia State University
Other
Eligibility
6 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia